Kiadis Pharma expands presence in the United States

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
84
Kiadis Pharma expands presence in the United States

                                                  

Kiadis Pharma expands presence in the United States

Scott Holmes commences position as chief financial officer Amy Sullivan appointed senior vice president, corporate affairs Both are based in Boston, Massachusetts

Amsterdam, The Netherlands, and Boston, Massachusetts, USA - January 4, 2019 - Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS ), a clinical-stage biopharmaceutical company, today announces that it has expanded its presence in the United States. Two of Kiadis' key interfaces for the financial markets are now based in Boston, with the previously announced appointment of Scott Holmes as chief financial officer and today's announcement of Amy Sullivan as senior vice president of corporate affairs, both effective January 1, 2019. Ms. Sullivan will replace Karl Hård, who resigned effective December 31 st to pursue other interests.

Arthur Lahr, CEO of Kiadis Pharma, commented: "I would like start by thanking Karl for his service to Kiadis and wishing him well in all his future endeavors.  I am excited to officially welcome both Scott and Amy to our company. They are a strong team and together bring a wealth of capital markets experience and strong relationships with the financial community to our company.  I look forward to working with them as we continue to raise awareness of Kiadis within the financial markets, as well as the medical community, in both the US and Europe."

Ms. Sullivan is a seasoned corporate affairs professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands.  Ms. Sullivan joins Kiadis from Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company's first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Idenix Biopharmacueticals and Genencor International. Earlier in her career, Ms. Sullivan served in roles of increasing responsibility in both agencies and Fortune 500 companies. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her masters of business administration from Bentley University.

Along with Mr. Holmes, Ms. Sullivan will be based in Boston. She will be responsible for investor relations, corporate communications and public affairs for Kiadis.

For more information, please contact:

Kiadis Pharma: Amy Sullivan, SVP, Corporate Affairs Tel. +1 508 479 3480 a.sullivan@kiadis.com Optimum Strategic Communications: Mary Clark, Supriya Mathur, Hollie Vile Tel: +44 203 714 1787 David Brilleslijper (Amsterdam) Tel: +31 610 942 514 kiadis@optimumcomms.com  

About Kiadis Pharma Kiadis Pharma is developing its lead product candidate, ATIR101, for use in conjunction with haploidentical HSCT for adult blood cancers to address key limitations of haploidentical HSCT, without prophylactic immunosuppression and its associated morbidity and mortality. Based on the positive results from the single dose Phase II CR-AIR-007 study, the Company submitted a marketing authorization application to the European Medicines Agency in April 2017 for approval of ATIR101 as an adjunctive treatment in haploidentical HSCT for high risk adult hematological malignancies. If the product is conditionally approved, Kiadis Pharma intends to launch ATIR101 in selected countries in Europe through its own commercial organization starting in the second half of 2019.

In December 2017, Kiadis Pharma commenced an international, multicenter, randomized and controlled Phase III clinical trial of ATIR101 against the Post-Transplant Cyclophosphamide, or PTCy protocol, the main protocol used to perform a haploidentical HSCT. The trial will be performed in 250 patients with acute leukemia and myelodysplastic syndrome at approximately 50 sites in the United States, Canada, Europe and certain additional countries. ATIR101 received regenerative medicine advanced therapy designation from the FDA in September 2017, which provides benefits that are materially equivalent to a breakthrough designation from the FDA. In addition, ATIR101 has been granted multiple orphan drug designations both in the European Union and the United States.

The Company's shares are listed on Euronext Amsterdam and Brussels under the ticker KDS.

Forward Looking Statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 66

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 49

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 191

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 11

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 161

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 18

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 70

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth Forecast for Vehicle Leasing Market in Europe by 2029

Updated Category News Views 185

Understanding the European Vehicle Leasing Market The vehicle leasing market in Europe is poised for substantial growth, with projections indicating an increase by USD 10.1 billion from 2025 to 2029. This market expansion is largely fueled by cost-effective strategies for acquiring vehicles, combined with a growing preference for leasing over purchasing vehicles outright....

Continue Reading
Creative Realities Welcomes Tamra Koshewa as CFO

Updated Category News Views 213

Creative Realities Strengthens Leadership with New CFO Creative Realities, Inc. (NASDAQ: CREX) has announced the appointment of Tamra Koshewa as its Chief Financial Officer, set to take on her new role in the upcoming month. With a rich history spanning three decades in the finance sector, Koshewa brings a wealth of knowledge and expertise that will be vital to the...

Continue Reading
Explore the Unique Ecosystem of Angry Pepe Fork and its Future

Updated Category News Views 210

A New Era for Meme Coins with Angry Pepe Fork In the fast-paced and ever-evolving world of cryptocurrencies, Angry Pepe Fork ($APORK) is making waves by offering a fresh and exciting approach to meme coins. As the market becomes more crowded, projects like Angry Pepe Fork are not just following trends; they're setting them. With the official announcement of their roadmap...

Continue Reading
Understanding Dow's Current Bearish Options Activities

Updated Category News Views 231

Understanding Dow's Current Bearish Options Activities In recent trading sessions, investors have taken a notably bearish stance on Dow (DOW). This growing trend among deep-pocketed investors indicates shifts that market players should heed. The unusual options activity surrounding Dow highlights a significant movement worth analyzing. Although the identities of these...

Continue Reading
Unlocking Investment Growth: The TRV Success Story Revealed

Updated Category News Views 120

Understanding Growth: A Look at Travelers Companies Travelers Companies has demonstrated impressive performance in the stock market, reflecting a consistent investment strategy that appeals to many investors. Over the last five years, the company has remarkably exceeded market expectations, returning an average of 17.18% annually, showcasing its potential for substantial...

Continue Reading